Compounds, compositions and methods
US-2016115133-A1 · Apr 28, 2016 · US
Salt of omecamtiv mecarbil and process for preparing salt
US9988354B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9988354-B2 |
| Application number | US-201414773436-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 14, 2014 |
| Priority date | Mar 14, 2013 |
| Publication date | Jun 5, 2018 |
| Grant date | Jun 5, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Provided are omecamtiv mecarbil dihydrochloride salt forms, compositions and pharmaceutical formulations thereof, and methods for their preparation and use. Omecamtiv mecarbil (AMG 423, CK-1827452), having the structure:
First claim
Opening claim text (preview).
What is claimed: 1. A dihydrochloride monohydrate salt of omecamtiv mecarbil. 2. A dihydrochloride monohydrate salt of omecamtiv mecarbil, wherein the salt is crystalline and is characterized by an X-ray powder diffraction pattern comprising peaks at about 6.6, 14.9, 20.1, 21.4, and 26.8±0.2° 2θ using Cu Kα radiation. 3. The salt of claim 2 , wherein the X-ray powder diffraction patter further comprises peaks at about 8.4, 24.2, 26.0, and 33.3±0.2° 2θ using Cu Kα radiation. 4. The salt of claim 2 , wherein the X-ray powder diffraction patter further comprises peaks at about 6.2, 9.7, 13.2, 14.3, 15.4, 16.3, 16.9, 18.9, 19.5, 20.7, 21.8, 22.8, 23.6, 25.1, 27.3, 27.7, 28.4, 29.4, 30.2, 31.2, 31.5, 31.9, 33.9, 34.5, 34.9, 36.1, 36.8, 37.7, 38.5, and 39.7±0.2° θ using Cu Kα radiation. 5. The salt of claim 2 , having an X-ray powder diffraction pattern substantially as shown in FIG. 2 . 6. The salt of claim 2 , having an endothermic transition at about 230° C. to about 240° C., as measured by differential scanning calorimetry. 7. The salt of claim 6 , wherein the endothermic transition is at about 235° C.
Assignees
Inventors
Classifications
Drugs for disorders of the cardiovascular system · CPC title
Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure · CPC title
Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose · CPC title
Cellulose; Derivatives thereof · CPC title
Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9988354B2 cover?
- Provided are omecamtiv mecarbil dihydrochloride salt forms, compositions and pharmaceutical formulations thereof, and methods for their preparation and use. Omecamtiv mecarbil (AMG 423, CK-1827452), having the structure:
- Who is the assignee on this patent?
- Amgen Inc
- What technology area does this patent fall under?
- Primary CPC classification C07D213/75. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jun 05 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).